UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): October 9, 2003

                             STAAR SURGICAL COMPANY
             (Exact name of registrant as specified in its charter)

           Delaware                     0-11634                  95-3797439
 (State or other jurisdiction)   (Commission File Number)      (I.R.S. Employer
of incorporation or organization)                            Identification No.)

 1911 Walker Avenue, Monrovia, California                                91016
 (Address of principal executive offices)                             (Zip Code)

                                 (626) 303-7902
              (Registrant's telephone number, including area code)








         The  information  furnished  with this  report  will not be  treated as
"filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or
otherwise subject to the liabilities of that section.  This information will not
be  incorporated by reference into a filing under the Securities Act of 1933, or
into another filing under the Exchange Act, unless that filing  expressly refers
to specific information in this report.

Item 7.  Financial Statements and Exhibits

         (c) Exhibits

Exhibit Number                Description
--------------                -----------

99.1     Press Release dated October 9, 2003.

99.2     Transcript of a conference call conducted by STAAR Surgical Company on
         October 9, 2003.

Item 9.  Regulation FD Disclosure.

         On October 9, 2003, the Company  conducted a conference call to discuss
the recommendation by the U.S. Food and Drug  Administration  Ophthalmic Devices
Panel of the Center for  Devices  and  Radiological  Health  that the  Company's
Implantable  Contact  Lens(TM)  (ICL(C)),  a  phakic  implant  used  to  correct
refractive  errors,  be approved with conditions for use in correcting myopia in
the range of -3 diopters to -15 diopters and reducing myopia in the range of -15
diopters to -20 diopters.  A transcript of the conference call is furnished with
this report as Exhibit 99.2 and is incorporated herein by this reference.

Item 12. Results of Operations and Financial Condition.

         On October 9, 2003,  the Company  issued a press  release  announcing a
preliminary  estimate of revenue for the third fiscal quarter of 2003. A copy of
the press release is attached as Exhibit 99.1 to this report and is incorporated
herein by this reference.

         The  preliminary  estimate of revenue was also discussed in the October
9, 2003  conference  call described under Item 9. That discussion is included in
the  transcript of the call  furnished  with this report as Exhibit 99.2, and is
incorporated herein by this reference.

                                      -2-




                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.


Date:   October 10, 2003                        STAAR SURGICAL COMPANY


                                                By: /s/ John Bily
                                                    ___________________
                                                    John Bily
                                                    Chief Financial Officer





                                      -3-




                                  Exhibit Index




EXHIBIT NUMBER                DESCRIPTION
--------------                -----------

99.1     Press Release dated October 9, 2003.

99.2     Transcript of a conference call conducted by STAAR Surgical Company on
         October 9, 2002.









                                      -4-